Project Topics Seminar Topics Post UTME Nursing Exam Past Questions
Search Topic
PARKLYN
ERVICES
· RC: 2994849
The Impact of Marginal Cost Components on Pharmaceutical Companies' Financial Performance in Nigeria

The Impact of Marginal Cost Components on Pharmaceutical Companies' Financial Performance in Nigeria

@SparklynServices
WhatsApp Channel

DEDICATION

This research material, titled “The Impact of Marginal Cost Components on Pharmaceutical Companies' Financial Performance in Nigeria” is dedicated to God for His boundless grace and guidance. It is also a tribute to all computer enthusiasts whose contributions made my research journey smoother and enriched my documentation process, making the experience truly fulfilling.




ACKNOWLEDGEMENT

I am profoundly grateful to everyone who contributed to the successful completion of this project. I am especially grateful to my Supervisor (Name), the Head of Department (Name), and the Lecturers in the Department of Public Administration (PA) for their invaluable guidance and support. I also acknowledge the contributions of authors and scholars whose works on The Impact of Marginal Cost Components on Pharmaceutical Companies' Financial Performance in Nigeria provided essential insights. Special thanks go to my study area (and any funding organizations, if applicable) for their financial assistance. I am equally thankful to stakeholders, including mentors, teachers, and colleagues, for their encouragement and support. Finally, I deeply appreciate my family and friends for their patience and unwavering support throughout this journey. Your contributions have been instrumental in making this research a reality.




PRELIMINARY PAGES


CHAPTER ONE

Introduction

  • 1.1 Background of the study 1
  • 1.2 Statement of the problem 3
  • 1.3 Objectives of the study 5
  • 1.4 Research questions 7
  • 1.5 Research hypotheses 8
  • 1.6 Significance of the study 9
  • 1.7 Scope and limitation of the study 10
  • 1.8 Definition of terms 12

CHAPTER TWO

Related Literature Review

  • 2.1 Definition of marginal cost 14
  • 2.2 The principles of marginal costing 16
  • 2.3 Marginal Cost Element 17
  • 2.4 Marginal costing and decision making 20
  • 2.5 Financial statements as yardsticks for measuring financial performance. 23
  • 2.5.1 Categories of financial statements 25
  • 2.5.2 Purpose of financial statement by business entities 27
  • 2.6 Analysis of financial statements 27
  • 2.7 Management accounting theory of variable cost 36
  • 2.8 Theory of productivity 40
  • REFERENCES 47

CHAPTER THREE

Research Design and Methodology

  • 3.1 Research design 48
  • 3.2 Area of study 48
  • 3.3 Population of study 48
  • 3.4 Sample size 48
  • 3.5 Sources of data 48
  • 3.6 Analytical method/technique 48

CHAPTER FOUR

Presentation and Analysis of Data

  • 4.1 Analysis of data 52
  • 4.2 Granger causality tests 53
  • 4.2.1 Analysis of description statistics 55
  • 4.3 Presentation of analysis result 43
  • 4.3.1 Analysis of regression result 62
  • 4.4 Interpretation of Findings 64

CHAPTER FIVE

Summary of Findings, Conclusion and Recommendations

  • 5.1 Summary of findings 66
  • 5.2 Conclusion 67
  • 5.3 Recommendations 69
  • BIBLIOGRAPHY 71
  • APPENDIX



ABSTRACT

The broad objective of the study is to evaluate the effect of marginal cost elements on financial performance or pharmaceutical companies in Nigeria using GlaxoSmithKline consumers’ plc, May and Baker Nig. Plc, Neimeth international, may and Baker Nig. Plc as case studies. The specific objective however is to examine the impact of cost of sales, cost of research and development and selling and administration expenses on the ROA of the quoted companies. Five years secondary data from the annual report and accounts of the three companies quoted on the Nigeria stock exchange were collected and regression analysis was utilized in the data analysis. The study found a negative and insignificant relationship between cost of sales and ROA. Also, cost of research and development was found a negative and insignificant relationship with the ROA. Finally, selling and administration expenses had a positive but insignificant relationship with ROA. The study recommends that against others, marginal must be minimized to the barest minimum so as to maintain a high level of profitability.



The Impact of Marginal Cost Components on Pharmaceutical Companies’ Financial Performance in Nigeria



Introduction

1.1 Background Of The Study

Recently the common concern to every participant in a market economy is the magnitude at which price of goods are multiplied in recent time in Nigeria. This is in addition to the multiplier effects associated with the process of transacting business in Nigeria for instance as customers complain bitterly of exorbitant prices likewise pharmaceutical companies remain worried about how profitability returns in the face of ever increasing competition. Even low buying power of customer, low capacity utilization and international market that are characterized by differentiated products. As a result customers shift from one product to another in search of value that rarely comes despites their reaches to purchase. They are all confronted with higher price low quality adulteration and at times temporary scarcity in place of value for money objectives they pursue. The management of different companies also seeks for cover everywhere to justify low profitability return while trying to checkmate competition and its resultant effect on financial performance caused by product proliferation and limitations.

To satisfy the above multifarious requirement, pharmaceutical companies are advice to apply marginal cost elements which refer to the value of what is given up in order to produce that additional unit which are practically applied by evaluation of performance, profit planning through calculation of present value (PV) ratio of company to plan the activities in such a way that the profit can be actualized fixation of selling price decision making and cost control which help to increase profitability of a company. Therefore, it cost management is to be there should be added up and be managed by competent hands. Financial performance of a pharmaceutical company uses financial statement analysis as the most objective way to evaluate financial performance.

Financial analysis involves assessing the leverages profitability operational efficiency and solvency for company financial ratios are the principal tools used to conduct the analysis and the challenge knows which ratios to choose from and how to interpret the results.


1.2 Statement Of The Problem

This research is primarily carried out by marginal cost elements available to some pharmaceutical companies in Nigeria more also it goes ahead to relate the financial performance of these pharmaceutical companies to direct material direct labor and overhead respectively. Hence the research aims at evaluating financial performance of pharmaceutical companies using the marginal cost element as a yard stick.

Marginal costing is a techniques used in reporting costs and profit of a firm. There should be separation of cost into fixed and variable costs. In marginal costing product cost include variable production cost such has direct material, direct labor, direct production overhead expenses. It ignores fixed cost and semi-variable cost. The separation of cost into fixed and variable cost is difficult, in reality manufacturing can’t take place without plant facilities and equipment hence fixed manufacturing cost are part of the production and should not be excluded.

Marginal costing fail as to take into consideration that in the long run, fixed cost will be part of the total cost of production than of a unit of an item. It is therefore not an appropriate tool in making pricing decision of a firm.

In the preparation of profit and loss account, the use of marginal cost is limited to the internal parties of a firm such as the management. In computing profit for tax purpose, marginal costing is not accepted method, because it does not include all cost used in production process. Therefore in preparation of profit and loss account meant for external uses such as shareholder investors, government and the public, using marginal costing will not present true and fair view of the financial affairs of the firm.


1.3 Objectives Of The Study

The primary objective of the study is to evaluate the effect of marginal cost element on financial performance pharmaceutical companies in Nigeria using Glaxosmithkline consumers’ plc, may and baker Nigeria plc, Neimeth international as case studies as well as determines its impact with respect to their profitability.

Above all, this study aims at highlighting the various marginal cost elements and it contributions to the effectiveness and efficient running of pharmaceutical companies.

The specific objectives of the study are

  1. To ascertain the relationship between cost of sales and financial performance to pharmaceutical companies in Nigeria.
  2. To determine the relationship between research and development expenses and financial performance of pharmaceutical companies in Nigeria.
  3. To determine the relationship between selling and administration expenses and financial performance of pharmaceutical companies in Nigeria.

1.4 Research Question

The following question would be consider relevant for the study based on the objectives of the study:

  1. What extent is cost of sales related financial performance?
  2. What kind of relationship exists between research and development expenses and financial performance of pharmaceutical companies in Nigeria?
  3. To what extent is selling and administered expense related to financial performance of pharmaceutical companies in Nigeria?

1.5 Research Hypothesis

In this research work the researcher formulated a number of research hypothesis in which the study will be based on. The hypothesis used includes null hypothesis “Ho” and alternative hypothesis “Hi”.

  1. Ho: There is no significant relationship between cost of sales and financial performance pharmaceutical companies in Nigeria.
    Hi: There is a significant relationship between cost of sales and financial performance pharmaceutical companies in Nigeria.
  2. Ho: There is no significant relationship between research and development expenses and financial performance of pharmaceutical companies.
    Hi: There is a significant relationship between research of pharmaceutical companies.
  3. Ho: There is no significant relationship between selling and administration expenses and financial performance of pharmaceutical companies in Nigeria.
    Hi: There is significant relationship between selling and administration expenses and financial performance of pharmaceutical companies in Nigeria.

1.6 Significance Of The Study

The aim of this study is to stimulated the interest of people on the implication of marginal cost on the financial performance of pharmaceutical companies and how it would further serve as a guide or reference for the younger and future researcher who may carryout research investigation in this area of study. It will in no doubt be of no importance to the companies using case studies of Glaxosmithkline consumers plc, may and Baker Nig. Plc, Neimeth international, because the findings will assist the companies in the following areas: increases the company’s profit marginal, help in reduction of marginal costs, help in the proper classification of the marginal cost into variable and fixed costs.


1.7 Scope And Limitation Of The Study

This research work is central on the effect of marginal cost element on the financial performance of pharmaceutical companies specifically Glexosmithkline consumer plc, may and Baker Nigeria plc, and Neimeth international and will endeavor to show all relevant information that will enhance the actualization of the research objectives put into place. The researcher would have carried out research work into a big and well known company but for the constraints that confronted there she limited her research works to the nearest pharmaceutical company specifically. The researcher was constrained by the following problems.


CHAPTER TWO

2.0 Literature Review

2.1 Introduction

This chapter focuses on the review of related literature. A literature review includes the current knowledge as well as theoretical and methodological contributions to a particular topic. It documents the state of the art with respect to the topic you are writing. It surveys the literature in the topic selected. In this research work the literature review includes the conceputal review, theoretical framework, the review of related literature …

Procedure for Accessing and Downloading the Complete Material in PDF or DOCX Format

Above is a preview excerpt of the full study on “The Impact of Marginal Cost Components on Pharmaceutical Companies’ Financial Performance in Nigeria”. The complete material, including all five chapters, is available for download upon request.


To obtain the complete research material content, simply place an order by paying the specified project or seminar fee using the account details or electronic payment (E-payment) system provided below.


Seminar Material
₦3,000
Project Material
₦5,000

For Mobile Money (MoMo) and Researchers Outside Nigeria, Kindly Request Complete Material via WhatsApp.


Account Details - For USSD / POS Transfer

ACCT NAMESPARKLYN SERVICES
Zenith Bank PLC1222599051
MoniePoint (MFB)8030511988
Paycom (OPay)8030511988

–– or ––



After payment, send message containing your payment receipt to Sparklyn Services with the phone number displayed below.


Once payment is confirmed, the complete document will be delivered via WhatsApp or email in Microsoft Word (MS-Word) format.




You can get more research topics on Public Administration, if you did not see your preferred topic from the alternate list above.

Defense Procedure for Public Administration Researchers


In preparation for defending a project or seminar on The Impact of Marginal Cost Components on Pharmaceutical Companies' Financial Performance in Nigeria, it is imperative that as a nursing student, you demonstrate comprehensive knowledge of your research. The defense process is structured to include presenting your work, answering questions, and illustrating its pertinence. Initially, provide a succinct yet thorough introduction to your research topic, emphasizing its importance and the objectives, ensuring that both the audience and the External Examiner can understand the scope of your study.


Prior to your defense, be thoroughly acquainted with your research abstract and the critical elements of Chapter One, including motivation for embarking on this research, problem statement, objectives, and significance. In Chapter Two, be ready to cite at least two references from the literature review. For Chapter Three, you should be equipped to discuss the methodologies, tools, and techniques utilized. In Chapter Four, defend your research by justifying the findings and linking them to your research objectives.


Conclude your defense by succinctly summarizing the study and offering insightful, evidence-based recommendations. A professional dress code, such as wearing a suit and tie, is vital to create a favorable impression and elevate your presentation.


During the question and answer segment, the External Examiner may pose questions pertaining to your research. If confronted with a challenging or irrelevant question, respond diplomatically with, “Sorry, Sir/Madam, the question asked is beyond the scope of my study.” Whenever possible, direct your answers back to your research findings to reinforce your expertise.


Page Content Headings - The Impact of Marginal Cost Components on Pharmaceutical Companies’ Financial Performance in Nigeria

    Download Material (Docx)